Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 or ≤75 years old at screening, regardless of gender; * Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP); * Compliant with GPP acute onset; * Able to read and understand, and willing to sign the informed consent form; * Willing and compliant with study visits and related procedures; * Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study; Exclusion Criteria: * Pustules are limited to psoriasis vulgaris on psoriasis plaques; * Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response; * Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator: * Serum virological abnormalities during the screening period; * Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test; * History of serious infection leading to hospitalization within 2 months prior to baseline; * Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment; * History of opportunistic infection within 6 months prior to baseline; * Received live (attenuated) vaccine treatment within 12 weeks prior to baseline; * Any major surgery within 4 weeks prior to baseline or planned major surgery during the study; * Received blood transfusion within 4 weeks prior to baseline; * Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline; * Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status; * Subjects with any type of active malignancy or a history of malignancy; * Alcohol, drug and known drug dependence; * Pregnant or lactating women; * Subjects cannot tolerate intravenous infusion administration.